Research Progress of Vimentin in Common Gynecological Malignancies

doi:10.12280/gjfckx.20230615

Abstract

Abstract:

Vimentin is an important type Ⅲ intermediate filament protein, mainly derived from mesenchymal cells. Vimentin is expressed in various types of tumors, and up-regulated expression of Vimentin is related to the migration and invasion ability of tumor cells, suggesting poor prognosis. Vimentin is a typical marker of epithelial-mesenchymal transition of tumor cells and a potential drug target. Studies have shown that Vimentin is abnormally expressed in cervical cancer, ovarian cancer and endometrial cancer, and is related to prognosis, tumormetastasis and recurrence, which has potential clinical application value. This article reviews the relationship between Vimentin as well as gynecological malignancy and its possible mechanism.

Key words: Vimentin, Uterine cervical neoplasms, Ovarian neoplasms, Endometrial neoplasms, Prognosis

WU Xia, JIN Yu-nan, FAN Yu-yu, SUO Yu-ping. Research Progress of Vimentin in Common Gynecological Malignancies[J]. Journal of International Obstetrics and Gynecology, 2023, 50(6): 655-659.

References 32

[1]	Infante E, Etienne-Manneville S. Intermediate filaments: Integration of cell mechanical properties during migration[J]. Front Cell Dev Biol, 2022, 10:951816. doi: 10.3389/fcell.2022.951816.
[2]	Karoii DH, Azizi H, Amirian M. Signaling Pathways and Protein-Protein Interaction of Vimentin in Invasive and Migration Cells: A Review[J]. Cell Reprogram, 2022, 24(4):165-174. doi: 10.1089/cell.2022.0025.
[3]	Ostrowska-Podhorodecka Z, Ding I, Norouzi M, et al. Impact of Vimentin on Regulation of Cell Signaling and Matrix Remodeling[J]. Front Cell Dev Biol, 2022, 10:869069. doi: 10.3389/fcell.2022.869069.
[4]	Strouhalova K, Přechová M, Gandalovičová A, et al. Vimentin Intermediate Filaments as Potential Target for Cancer Treatment[J]. Cancers(Basel), 2020, 12(1):184. doi: 10.3390/cancers12010184.
[5]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590. doi: 10.1097/CM9.0000000000002108.
[6]	Mogre S, Makani V, Pradhan S, et al. Biomarker Potential of Vimentin in Oral Cancers[J]. Life(Basel), 2022, 12(2):150. doi: 10.3390/life12020150.
[7]	Ridge KM, Eriksson JE, Pekny M, et al. Roles of vimentin in health and disease[J]. Genes Dev, 2022, 36(7/8):391-407. doi: 10.1101/gad.349358.122.
[8]	Schaedel L, Lorenz C, Schepers AV, et al. Vimentin intermediate filaments stabilize dynamic microtubules by direct interactions[J]. Nat Commun, 2021, 12(1):3799. doi: 10.1038/s41467-021-23523-z. pmid: 34145230
[9]	Arrindell J, Desnues B. Vimentin: from a cytoskeletal protein to a critical modulator of immune response and a target for infection[J]. Front Immunol, 2023, 14:1224352. doi: 10.3389/fimmu.2023.1224352.
[10]	Berr AL, Wiese K, Dos Santos G, et al. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer[J]. Oncogene, 2023, 42(25):2074-2087. doi: 10.1038/s41388-023-02703-9. pmid: 37161053
[11]	Usman S, Waseem NH, Nguyen T, et al. Vimentin Is at the Heart of Epithelial Mesenchymal Transition(EMT) Mediated Metastasis[J]. Cancers(Basel), 2021, 13(19):4985. doi: 10.3390/cancers13194985.
[12]	Chiou WC, Huang C, Lin ZJ, et al. α-Viniferin and ε-Viniferin Inhibited TGF-β1-Induced Epithelial-Mesenchymal Transition, Migration and Invasion in Lung Cancer Cells through Downregulation of Vimentin Expression[J]. Nutrients, 2022, 14(11):2294. doi: 10.3390/nu14112294.
[13]	Yuan RQ, Zhao H, Wang Y, et al. SEPTIN9-SDC2-VIM methylation signature as a biomarker for the early diagnosis of colorectal cancer[J]. Am J Cancer Res, 2022, 12(7):3128-3140.
[14]	Cheng Y, Zhou Y, Jiang W, et al. Significance of E-cadherin, β-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma[J]. Hum Pathol, 2012, 43(8):1213-1220. doi: 10.1016/j.humpath.2011.08.025. pmid: 22221700
[15]	Lin J, Lu J, Wang C, et al. The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer[J]. Cancer Cell Int, 2017, 17:80. doi: 10.1186/s12935-017-0450-6. pmid: 28912668
[16]	Yu JQ, Zhou Q, Zheng YF, et al. Expression of Vimentin and Ki-67 Proteins in Cervical Squamous Cell Carcinoma and their Relationships with Clinicopathological Features[J]. Asian Pac J Cancer Prev, 2015, 16(10):4271-4275. doi: 10.7314/apjcp.2015.16.10.4271.
[17]	Lee MK, Jeong EM, Kim JH, et al. Aberrant methylation of the VIM promoter in uterine cervical squamous cell carcinoma[J]. Oncology, 2014, 86(5/6):359-368. doi: 10.1159/000362738.
[18]	Jung S, Yi L, Kim J, et al. The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer[J]. Mol Cells, 2011, 31(5):405-411. doi: 10.1007/s10059-011-0229-x. pmid: 21491170
[19]	Liu Y, Wang Y, Chen C, et al. LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter[J]. Oncotarget, 2017, 8(7):11329-11342. doi: 10.18632/oncotarget.13516. pmid: 27894088
[20]	Zhang J, Liu HL, Liu JB, et al. LncRNA AL592284.1 facilitates proliferation and metastasis of cervical cancer cells via miR-30a-5p/Vimentin/EMT axis[J]. Biochem Biophys Res Commun, 2021, 577:95-102. doi: 10.1016/j.bbrc.2021.09.014.
[21]	Zamulaeva I, Matchuk O, Selivanova E, et al. Effects of Fractionated Radiation Exposure on Vimentin Expression in Cervical Cancers: Analysis of Association with Cancer Stem Cell Response and Short-Term Prognosis[J]. Int J Mol Sci, 2023, 24(4):3271. doi: 10.3390/ijms24043271.
[22]	Goel A, Rao NM, Santhi V, et al. Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to Cytokeratin and Vimentin[J]. Iran J Pathol, 2018, 13(1):23-29. doi:10.30699/IJP.13.1.23.
[23]	Desouki MM, Kallas SJ, Khabele D, et al. Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors[J]. Int J Gynecol Pathol, 2014, 33(3):274-281. doi: 10.1097/PGP.0b013e31829040b5. pmid: 24681739
[24]	Szubert S, Koper K, Dutsch-Wicherek MM, et al. High tumor cell vimentin expression indicates prolonged survival in patients with ovarian malignant tumors[J]. Ginekol Pol, 2019, 90(1):11-19. doi: 10.5603/GP.2019.0003. pmid: 30756366
[25]	Li X, Yang J, Wang X, et al. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression[J]. Eur J Gynaecol Oncol, 2016, 37(1):100-108. doi:10.12892/ejgo2691.2016. pmid: 27048119
[26]	Soovares P, Pasanen A, Similä-Maarala J, et al. Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade[J]. Gynecol Oncol, 2022, 164(1):187-194. doi: 10.1016/j.ygyno.2021.10.078.
[27]	Dionísio de Sousa IJ, Marques DS, Príncipe C, et al. Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer[J]. Diagnostics(Basel), 2020, 10(8):525.doi: 10.3390/diagnostics10080525.
[28]	Han X, Zhou Y, You Y, et al. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer[J]. Cell Biol Int, 2017, 41(4):405-414. doi: 10.1002/cbin.10734. pmid: 28150354
[29]	Zhao L, Zhang P, Su XJ, et al. The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin[J]. J Cell Physiol, 2018, 233(3):2420-2425. doi: 10.1002/jcp.26114. pmid: 28771721
[30]	Han CP, Lee MY, Kok LF, et al. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study[J]. Arch Gynecol Obstet, 2010, 281(5):845-850. doi: 10.1007/s00404-009-1151-8.
[31]	Zhang X, Cao G, Diao X, et al. Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma[J]. Dis Markers, 2022, 2022:5240046. doi: 10.1155/2022/5240046.
[32]	Lien HE, Berg HF, Halle MK, et al. Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease[J]. EBioMedicine, 2023, 92:104595. doi: 10.1016/j.ebiom.2023.104595.